Along with her clinical expertise, Dr. Desai is also using pharmacology and biomarker data to explore new therapies for solid tumors.. Through this research, she is examining how the body reacts to drug treatments in order to reduce toxicity, improve patient response to medication and enhance overall health and outcomes. Dr. Desai has served as the lead investigator in multiple research studies and her work has been published in peer-review journals such as: Pediatric Blood and Cancer, Cancer Chemotherapy Pharmacology and the Bone Marrow Transplantation.
Areas of Expertise
- Sarcomas
- Solid Tumors in Children
- Cancer Risk and Prevention
- Developmental Therapeutics
- Neuroblastoma
- Adolescent and Young Adult (AYA) Cancer Care
- Solid Tumors
Board Certifications
- Pediatric Hematology and Oncology
- Pediatrics
Memberships & Medical Societies
- American Association for Cancer Research
- American Society of Pediatric Hematology/Oncology
- Children?s Oncology Group
- American Society of Clinical Oncology
- Connective Tissue Oncology Society
Practicing Since
- 2013
Languages Spoken
- English
Medical Education
- Robert Wood Johnson Medical School
Residency
- Yale New Haven Hospital
Fellowship
- Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania
Other Grad Education
- University of Pennsylvania,MSCE
News & Research
View Published Papers- Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Neuroblastoma Biology Study
- Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- MIBG With Dinutuximab +/- Vorinostat
- A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
- A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
- Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Comer Children's Hospital - Hyde Park
Request an Appointment at Comer Children's Hospital - Hyde Park
To Refer a Patient
Refer a Patient